CA2475190C - Vaccin - Google Patents

Vaccin Download PDF

Info

Publication number: CA2475190C
Authority: CA; Canada
Prior art keywords: bacterium; rhodococcus; pmws; pdns; immune modulator
Prior art date: 2004-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2475190A

Other languages

English (en)

Other versions

CA2475190A1 (fr

Inventor

Oscar Adelmo Bottasso

Graham Mcintyre

Cynthia Ann Stanford

John Lawson Stanford

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

UCL Business Ltd

Original Assignee

UCL Biomedica PLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-19

Filing date

2004-07-19

Publication date

2012-11-20

2004-07-19 Application filed by UCL Biomedica PLC filed Critical UCL Biomedica PLC

2004-07-19 Priority to CA2475190A priority Critical patent/CA2475190C/fr

2006-01-19 Publication of CA2475190A1 publication Critical patent/CA2475190A1/fr

2012-11-20 Application granted granted Critical

2012-11-20 Publication of CA2475190C publication Critical patent/CA2475190C/fr

2024-07-19 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

208000028489 postweaning multisystemic wasting syndrome Diseases 0.000 title claims abstract description 47
241000316848 Rhodococcus <scale insect> Species 0.000 title claims abstract description 23
239000000203 mixture Substances 0.000 claims abstract description 59
241000894006 Bacteria Species 0.000 claims abstract description 49
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
208000011580 syndromic disease Diseases 0.000 claims abstract description 22
238000011282 treatment Methods 0.000 claims abstract description 16
208000017169 kidney disease Diseases 0.000 claims abstract description 12
201000004624 Dermatitis Diseases 0.000 claims abstract description 11
230000002265 prevention Effects 0.000 claims abstract description 9
239000003814 drug Substances 0.000 claims abstract description 6
238000004519 manufacturing process Methods 0.000 claims abstract description 6
241001465754 Metazoa Species 0.000 claims description 22
244000144972 livestock Species 0.000 claims description 10
241000187563 Rhodococcus ruber Species 0.000 claims description 4
241000894007 species Species 0.000 claims description 4
241001524101 Rhodococcus opacus Species 0.000 claims description 3
241001518123 Rhodococcus rhodnii Species 0.000 claims description 3
210000003022 colostrum Anatomy 0.000 claims description 2
235000021277 colostrum Nutrition 0.000 claims description 2
241001524109 Dietzia Species 0.000 abstract description 15
241001337904 Gordonia <angiosperm> Species 0.000 abstract description 15
241000187654 Nocardia Species 0.000 abstract description 15
241000187580 Nocardioides Species 0.000 abstract description 15
241000204066 Tsukamurella Species 0.000 abstract description 15
238000000034 method Methods 0.000 abstract description 7
108091007433 antigens Proteins 0.000 description 32
102000036639 antigens Human genes 0.000 description 32
239000000427 antigen Substances 0.000 description 31
229960005486 vaccine Drugs 0.000 description 24
210000004027 cell Anatomy 0.000 description 22
241000282887 Suidae Species 0.000 description 21
230000000890 antigenic effect Effects 0.000 description 20
239000002671 adjuvant Substances 0.000 description 18
230000004044 response Effects 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
239000007924 injection Substances 0.000 description 12
238000002347 injection Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 12
229960001438 immunostimulant agent Drugs 0.000 description 11
239000003022 immunostimulating agent Substances 0.000 description 11
230000003308 immunostimulating effect Effects 0.000 description 11
239000000126 substance Substances 0.000 description 11
230000028993 immune response Effects 0.000 description 10
201000010099 disease Diseases 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
230000036755 cellular response Effects 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
210000002443 helper t lymphocyte Anatomy 0.000 description 6
239000000243 solution Substances 0.000 description 6
229960001005 tuberculin Drugs 0.000 description 6
230000024932 T cell mediated immunity Effects 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
239000000902 placebo Substances 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000282898 Sus scrofa Species 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000007922 nasal spray Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
241001533384 Circovirus Species 0.000 description 3
108010041986 DNA Vaccines Proteins 0.000 description 3
229940021995 DNA vaccine Drugs 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000187644 Mycobacterium vaccae Species 0.000 description 3
241001518128 Rhodococcus coprophilus Species 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
241000193830 Bacillus <bacterium> Species 0.000 description 2
241000238424 Crustacea Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
102000002812 Heat-Shock Proteins Human genes 0.000 description 2
108010004889 Heat-Shock Proteins Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
201000005702 Pertussis Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
241000224016 Plasmodium Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010043376 Tetanus Diseases 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
-1 carrier Substances 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
206010013023 diphtheria Diseases 0.000 description 2
229960003983 diphtheria toxoid Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
244000144980 herd Species 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
201000004792 malaria Diseases 0.000 description 2
229940041323 measles vaccine Drugs 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229940095293 mumps vaccine Drugs 0.000 description 2
229940097496 nasal spray Drugs 0.000 description 2
244000045947 parasite Species 0.000 description 2
229940066827 pertussis vaccine Drugs 0.000 description 2
229960001539 poliomyelitis vaccine Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
229960003131 rubella vaccine Drugs 0.000 description 2
238000003307 slaughter Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
208000020154 Acnes Diseases 0.000 description 1
241000606750 Actinobacillus Species 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241001524110 Dietzia maris Species 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
241001509405 Gordonia amarae Species 0.000 description 1
241000203749 Gordonia bronchialis Species 0.000 description 1
241000203747 Gordonia terrae Species 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
206010024642 Listless Diseases 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000187678 Nocardia asteroides Species 0.000 description 1
241000187606 Nocardioides albus Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
241000283903 Ovis aries Species 0.000 description 1
241000606860 Pasteurella Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
241000146299 Tsukamurella inchonensis Species 0.000 description 1
241000204063 Tsukamurella paurometabola Species 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000000961 alloantigen Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229940001007 aluminium phosphate Drugs 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000001132 aluminium potassium sulphate Substances 0.000 description 1
235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
244000309466 calf Species 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000012677 causal agent Substances 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
230000001236 detergent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010410 dusting Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000036541 health Effects 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
208000021760 high fever Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000002134 immunopathologic effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000007803 itching Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
HEHQDWUWJVPREQ-XQJZMFRCSA-N lipid X Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)C[C@H](O)CCCCCCCCCCC HEHQDWUWJVPREQ-XQJZMFRCSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
208000017971 listlessness Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229940021993 prophylactic vaccine Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000003289 regulatory T cell Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000005204 segregation Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA2475190A 2004-07-19 2004-07-19 Vaccin Expired - Fee Related CA2475190C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2475190A CA2475190C (fr)	2004-07-19	2004-07-19	Vaccin

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2475190A CA2475190C (fr)	2004-07-19	2004-07-19	Vaccin

Publications (2)

Publication Number	Publication Date
CA2475190A1 CA2475190A1 (fr)	2006-01-19
CA2475190C true CA2475190C (fr)	2012-11-20

Family

ID=35637000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2475190A Expired - Fee Related CA2475190C (fr)	2004-07-19	2004-07-19	Vaccin

Country Status (1)

Country	Link
CA (1)	CA2475190C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109414463A (zh) *	2016-02-25	2019-03-01	托马斯·朱利叶斯·波洛迪	治疗慢性传染性疾病的组合物和方法

2004
- 2004-07-19 CA CA2475190A patent/CA2475190C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2475190A1 (fr)	2006-01-19

Legal Events

Date	Code	Title	Description
2009-04-22	EEER	Examination request
2019-08-31	MKLA	Lapsed	Effective date: 20190719

Publication	Publication Date	Title
Goodwin et al.	2016	Brucellosis vaccines for livestock
KR100374434B1 (ko)	2003-06-09	변형된소호흡관련합포체바이러스(brsv)생백신조성물
US8512694B2 (en)	2013-08-20	Method of producing rough strains of bacteria and uses thereof
US11696944B2 (en)	2023-07-11	Vaccine for protection against Streptococcus suis
Van der Stede et al.	2003	Reduced faecal excretion of F4+-E. coli by the intramuscular immunisation of suckling piglets by the addition of 1α, 25-dihydroxyvitamin D3 or CpG-oligodeoxynucleotides
CN1735431B (zh)	2010-05-12	作为免疫调节物的全细菌细胞
JP5101795B2 (ja)	2012-12-19	免疫モジュレーターとしての全細菌細胞
US7442374B2 (en)	2008-10-28	Composition for increasing the survival to slaughter rate of piglets
CA2475190C (fr)	2012-11-20	Vaccin
JP5523685B2 (ja)	2014-06-18	使用
JP2023113631A (ja)	2023-08-16	クロストリジウム類毒素を含むワクチン
Jarosova et al.	2023	Effects of oil-based adjuvants on the immune response of pigs after dermal administration of antigen and evaluation of the immunization level after a subsequent Actinobacillus pleuropneumoniae challenge in pigs
US20090162324A1 (en)	2009-06-25	Use of Whole Cell Actinomycetales Bacteria to Treat Stress-Induced Pulmonary Haemorrhage
Ward et al.	1999	Immunologic responses of domestic and bighorn sheep to a multivalent Pasteurella haemolytica vaccine